Australia's most trusted
source of pharma news
Monday, 07 October 2024
Posted 14 November 2022 AM
Last week the TGA waved through two innovative therapies including a dialysis product that CSL just recently added to its pipeline when it completed its mammoth Vifor Pharma acquisition.
The regulator approved the company's Korsuva, a first-in-class kappa opioid receptor agonist, indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.